An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions | Oncology and Therapy
Personalized Dosing of Niraparib in Ovarian Cancer - YouTube
Pivotal Trials in the Realm of Ovarian Cancer
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - ScienceDirect
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer | PPT
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - European Journal of
Niraparib in Patients With Newly Diagnosed Advanced Ovarian BRCAm Cancer: A Post Hoc Analysis of the PRIMA/ENGOT-OV26/GOG-3012 T
Efficacy of niraparib in the PRIMA trial | Download Scientific Diagram
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Estudo PRIMA: niraparib demonstra benefício na PFS a longo prazo no tratamento de 1.ª linha do cancro do ovário
PARP Inhibitors. - ppt download
Treatment and Maintenance Therapy in Advanced Ovarian Cancer | VuMedi
TESARO Pioneers Summit - ppt download
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
Efficacy | ZEJULA (niraparib) for HCPs
Efficacy | ZEJULA (niraparib) for HCPs
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
Efficacy of Niraparib by Timing of Surgery and Residual Disease: a Post Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-301
CME; Niraparib, Olaparib, bevacizumab, PRIMA trial, PAOLO-1
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context | Future Oncology
